Fig. 5.

GSI MRK003 antagonizes ET-resistant breast cancer cells through down-regulation of PBX1. (A) Growth assays in GSI-treated (MRK003 for HA-LTED and MK0572 for all other cell lines) or control-treated (CTRL) ET-resistant cells. (B) Microarray-based expression-profile analysis in LTED cells treated with the MRK003 GSI (Right) or transfected with siPBX1 (Left) are presented compared with their respective controls. All three replicates are shown. Genes whose expression is affected by both the MRK003 GSI and siPBX1 are presented (Center). (C) Oncomine Concepts Map analysis comparing the list of genes whose expression is down-regulated by both the MRK003 GSI and siPBX1 to expression signatures associated with breast tumors with poor outcome.